DAVID ALLISON to Anti-Obesity Agents
This is a "connection" page, showing publications DAVID ALLISON has written about Anti-Obesity Agents.
Connection Strength
1.720
-
FDA approval of obesity drugs: a difference in risk-benefit perceptions. JAMA. 2012 Sep 19; 308(11):1097-8.
Score: 0.403
-
Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012 Feb; 20(2):330-42.
Score: 0.379
-
Combination therapy for obesity and metabolic disease. Curr Opin Endocrinol Diabetes Obes. 2009 Oct; 16(5):353-8.
Score: 0.328
-
A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. Int J Obes Relat Metab Disord. 2004 Nov; 28(11):1411-9.
Score: 0.233
-
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb; 95(2):297-308.
Score: 0.095
-
Obesity: person and population. Obesity (Silver Spring). 2006 Jul; 14 Suppl 4:156S-159S.
Score: 0.065
-
PYY3-36 as an anti-obesity drug target. Obes Rev. 2005 Nov; 6(4):307-22.
Score: 0.062
-
Dietary supplements in weight reduction. J Am Diet Assoc. 2005 May; 105(5 Suppl 1):S80-6.
Score: 0.060
-
Rimonabant Sanofi-Synth?labo. Curr Opin Investig Drugs. 2004 Apr; 5(4):430-5.
Score: 0.056
-
Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 1998 Nov 11; 280(18):1596-600.
Score: 0.039